^
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
XP
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
docetaxel + irinotecan
Sensitive: A2 - Guideline
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
CaT
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
IP
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
NTRK3 fusion
Esophageal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Esophageal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Esophageal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Esophageal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Esophageal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Esophageal Cancer
entrectinib
Sensitive: A2 - Guideline
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FP
Sensitive: A2 - Guideline
TMB-H
Esophageal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
paclitaxel + capecitabine
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
DP
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
oxaliplatin
Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
XP
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
FP
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
DOF
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
carboplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
No biomarker
Esophageal Cancer
TPF
Sensitive: A2 - Guideline
No biomarker
Esophageal Adenocarcinoma
FOLFOX
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Esophageal Cancer
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: B - Late Trials
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
No biomarker
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive: B - Late Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: B - Late Trials
MSI-H/dMMR
Esophageal Cancer
dostarlimab
Resistant: C1 - Off-label
NTRK3 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C1 - Off-label
HER-2 overexpression
Esophageal Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive: C1 - Off-label
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C2 – Inclusion Criteria
MYC amplification
Esophageal Cancer
ibrutinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Cancer
ibrutinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
CLDN18.2 expression
Esophageal Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Esophageal Cancer
atezolizumab + MTIG7192A
Sensitive: C2 – Inclusion Criteria
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive: C3 – Early Trials
NDRG1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
SGK1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant: C3 – Early Trials
HER-2 positive
Esophageal Adenocarcinoma
paclitaxel
Resistant: C3 – Early Trials
HER-2 positive
Esophageal Adenocarcinoma
carboplatin
Resistant: C3 – Early Trials
AFAP1-AS1 overexpression
Esophageal Squamous Cell Carcinoma
FP
Resistant: C3 – Early Trials
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
camrelizumab
Sensitive: C3 – Early Trials
TLR signature
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: C3 – Early Trials
NDRG1-H
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Adenocarcinoma
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
DKN-01
Sensitive: C3 – Early Trials
DKK1 overexpression
Esophageal Adenocarcinoma
DKN-01
Sensitive: C3 – Early Trials
NFKB1 expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive: C3 – Early Trials
KDR expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive: C3 – Early Trials
PD-L1 overexpression + CCL5 overexpression
Esophageal Squamous Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
TMB-H
Esophageal Cancer
camrelizumab
Sensitive: C3 – Early Trials
GRB7 positive
Esophageal Adenocarcinoma
trastuzumab + carboplatin + paclitaxel + pertuzumab
Sensitive: C3 – Early Trials
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 positive
Esophageal Cancer
durvalumab
Resistant: C3 – Early Trials
ERCC1 negative
Esophageal Adenocarcinoma
SOX
Sensitive: C3 – Early Trials